Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02232581
Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT02231177
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® - inhaler
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 236
- Registration Number
- NCT02231320
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® solution for inhalation
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4602
- Registration Number
- NCT02231372
Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
Phase 2
Completed
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02231918
Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
Phase 4
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: BI-Sifrol®
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02231905
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® solution for inhalation
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2006
- Registration Number
- NCT02231359
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Phase 3
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02231164
- Locations
- 🇺🇸
1199.128.10032 Boehringer Ingelheim Investigational Site, Chandler, Arizona, United States
🇺🇸1199.128.10041 Boehringer Ingelheim Investigational Site, Fayetteville, Arkansas, United States
🇺🇸1199.128.10010 Boehringer Ingelheim Investigational Site, Highland, California, United States
Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02231931
- Locations
- 🇩🇪
352.2082.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Observational Study to Assess a 6-months Treatment With Gladem
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 546
- Registration Number
- NCT02231268